Mode
Text Size
Log in / Sign up

Evaluating Thrombectomy Efficacy and Safety in Patients with Medium or Distal Arterial OcclusionsTrial shows thrombectomy results for specific types of ischemic stroke

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Thrombectomy for MDVO did not improve 3-month outcomes compared to medical management and increased hemorrhage risk.

This randomized clinical trial evaluated the efficacy and safety of mechanical thrombectomy compared to medical management alone in 244 adult patients presenting with acute ischemic stroke (AIS) caused by a primary and isolated medium or distal arterial occlusion (MDVO). The study was conducted across 22 stroke centers in France, aiming to determine if surgical intervention provided superior clinical outcomes for this specific anatomical subset of patients.

The primary endpoint was the proportion of patients achieving a good clinical outcome at three months, defined as a modified Rankin Scale score of 0 to 2. In the intervention cohort, 62% of patients achieved this outcome, while 68% achieved it in the control group. Statistical analysis revealed no significant difference between the two groups (OR 0.73; 95% CI, 0.40-1.31; P =.29), suggesting that surgical intervention did not improve functional recovery for these specific occlusions.

Secondary outcomes included mortality rates and the incidence of adverse events. Mortality at three months was recorded at 6% for those receiving thrombectomy and 8% for those receiving medical treatment alone, with no statistically significant difference observed (P =.49). These results suggest that while thrombectomy is a standard of care for large vessel occlusions, its specific added value in distal or medium vessel segments remains nuanced in this population.

Safety data revealed significant differences in complication rates. Patients undergoing thrombectomy experienced a significantly higher rate of symptomatic intracranial hemorrhages (11% vs. 3%, P =.008) and subarachnoid hemorrhages (13% vs. 2%, P <.001). Additionally, the rate of embolus migration was higher in the intervention group (5% vs. 1%, P =.04). These findings indicate a higher risk of hemorrhagic complications associated with the surgical procedure.

Due to the observed lack of superior clinical outcomes and the increased rate of symptomatic intracranial hemorrhage, the trial was stopped early for futility. The data suggest that for patients with MDVO, the risks associated with mechanical intervention, specifically regarding hemorrhage, may outweigh the potential benefits in terms of functional recovery compared to standard medical management. Clinicians should consider these findings when managing patients with distal or medium arterial occlusions. While thrombectomy is often utilized for various stroke types, the specific risk-benefit profile for MDVO patients involves a higher incidence of serious hemorrhagic complications without a corresponding increase in the rate of favorable functional outcomes at three months. This evidence highlights the need for individualized risk-benefit assessments in the management of distal and medium vessel occlusions.

When a person suffers an ischemic stroke, every minute counts. A specific type of stroke, known as a medium or distal arterial occlusion, occurs when a blood clot blocks a smaller artery. For patients facing this condition, doctors must decide quickly on the best way to clear the blockage and restore blood flow to the brain. This research looked at whether adding a procedure called a thrombectomy to standard medical treatment improved the chances of a good recovery for these specific patients.

The study involved 244 adults who had just experienced this type of stroke. The patients were split into two groups. One group received standard medical treatment alone, while the other group received both medical treatment and a thrombectomy procedure. The researchers followed both groups for three months to see who achieved a good clinical outcome, which means the patient could perform daily activities with little to no disability. They also tracked the number of deaths and the occurrence of any serious complications.

The results showed that the procedure did not lead to a better recovery rate compared to medical treatment alone. In the thrombectomy group, 62 percent of patients had a good outcome, while 68 percent of patients in the medical treatment group reached the same goal. The difference was not statistically significant, meaning the procedure did not provide a clear advantage in terms of recovery. Additionally, the mortality rates were similar between both groups, with 6 percent in the thrombectomy group and 8 percent in the medical treatment group.

However, the study did find significant safety concerns. Patients who underwent the thrombectomy procedure were much more likely to experience serious bleeding in the brain. Specifically, symptomatic intracranial hemorrhages and subarachnoid hemorrhages were significantly more common in the group that received the procedure. There was also a higher rate of embolus migration, where a piece of the clot moves to another part of the brain. Because of these risks and the lack of improved outcomes, the trial was stopped early.

It is important to remember that this study focused on a very specific type of stroke involving medium or distal arteries. While the results are important for doctors making decisions in the emergency room, they do not mean that thrombectomy is ineffective for all types of strokes. Because the trial was stopped early due to safety concerns and a lack of clear benefit for this specific group, the findings are specific to this population. For now, these results suggest that for this particular type of stroke, the added risk of bleeding may outweigh the potential benefits of the procedure.

What this means for you:
Thrombectomy did not improve recovery for this specific stroke type and was linked to higher bleeding risks.

Study Details

Study typeRct
Sample sizen = 488
EvidenceLevel 2
Follow-up3.0 mo
PublishedSep 2026
View Original Abstract ↓
IMPORTANCE: Evidence regarding efficacy and safety of thrombectomy in acute ischemic stroke (AIS) due to medium or distal vessel occlusions (MDVOs) is lacking. OBJECTIVE: To evaluate the benefit of thrombectomy, in addition to medical treatment over medical treatment alone, in patients with an AIS related to a primary and isolated MDVO. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 22 stroke centers in France from November 2021 to April 2025, with planned enrollment of 488 patients. The trial has been stopped after the planned interim analysis on the recommendation of the data and safety monitoring board for futility and increased rate of symptomatic intracranial hemorrhage with thrombectomy. Eligible adult patients had an AIS due to a primary MDVO within 8 hours of symptom onset or within 24 hours of last seen well if no hyperintense signal was present on fluid-attenuated inversion recovery imaging. INTERVENTION: Thrombectomy in addition to medical treatment (n = 123) or medical treatment alone (n = 121). MAIN OUTCOMES AND MEASURES: The primary end point was a good clinical outcome at 3 months, defined as a modified Rankin Scale score of 0 to 2, assessed by an independent, blinded assessor. Secondary end points included mortality rate at 3 months and adverse and serious adverse events. RESULTS: Of the 244 patients randomized (median age, 75 years [IQR, 67-81]; 56% male; median National Institutes of Health Stroke Scale score, 8 [IQR, 6-12]), 100 of the 123 patients in the thrombectomy group (81%) received thrombectomy and none of the 121 patients in the control group received thrombectomy; 217 (89%) completed follow-up. At 3 months, 72 of 116 patients (62%) in the thrombectomy group had a good clinical outcome vs 81 of 119 patients (68%) in the control group (odds ratio, 0.73 [95% CI, 0.40-1.31]; P = .29; adjusted absolute difference, -6.8% [95% CI, -19.4% to 5.7%]). The incidence of symptomatic intracranial hemorrhages was higher among the 100 patients who actually received thrombectomy than in those who did not (11% vs 3%, P = .008), as was incidence of subarachnoid hemorrhages (13% vs 2%, P < .001) and embolus migration (5% vs 1%, P = .04). Mortality rate did not significantly differ between the 2 groups (6% vs 8%; P = .49). CONCLUSIONS AND RELEVANCE: Thrombectomy did not lead to a higher rate of good clinical outcome at 3 months compared with medical treatment alone in patients with acute ischemic stroke related to an MDVO. Hemorrhagic complications were more frequent after thrombectomy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05030142.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.